08 August 2018
Pfizer has tapped Antares Pharma for the development of a self-administered combination drug-device rescue pen for an undisclosed medicine, shortly after investing $465 million in a new sterile injectables plant.
Pfizer will pay for the product’s development and lead the push for FDA approval, while Antares will provide its QuickShot auto-injector.
Under a separate supply deal, Antares will deliver the finished, fully packaged product to Pfizer at cost, plus margin, while the Big Pharma will then be responsible for its commercialization. While full financial details are not available, Antares will receive royalties on net sales.
“We look forward to working closely with Pfizer throughout the development phase of this combination product and assisting them with the FDA drug device approval process,” Antares President and CEO Robert Apple said in a statement (PDF). The Ewing, New Jersey-based company’s stock was up more than 8% in premarket trading.
Pfizer’s massive, 400,000-square-foot addition planned for its Portage, Michigan, manufacturing plant is expected to add 450 new jobs when its fully operational in 2024.
The site is already one of the company’s primary facilities for sterile injectable, liquid and semisolid medicines—as well as for active pharmaceutical ingredients—and currently manufactures more than 150 products.
Pfizer previously contracted with Antares in a similar delivery device deal through its consumer health arm in 2011, with its targets and financial details undisclosed as well.
“This development agreement between Antares and Pfizer further expands our portfolio of pipeline-partnered products,” including the number of products using the company’s QuickShot auto-injector platform, Apple said.
Antares also maintains collaborations with Actavis, Meda, AMAG Pharmaceuticals and Teva. Antares’ other proprietary products include Otrexup (methotrexate) subcutaneous injection and the investigational testosterone replacement therapy Xyosted, currently under FDA review with decision expected by the end of September.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024